Posted inHematology-Oncology news Public Health
Global Disparities in CAR T-Cell Access: HTA Analysis Reveals Only Half of G20 Countries Recommend Reimbursement
A cross-sectional analysis of health technology assessments across G20 nations reveals significant disparities in access to CAR T-cell therapies, with only 48% of approved indications recommended for reimbursement and a median 1.54-year delay from FDA approval to HTA decision.